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Abstract
We have previously shown that lysates from HL-60 myeloid leukemia cells or from peripheral blood monocytes are able to degrade a-
actinin to form a 31-kDa amino-terminal fragment with monocyte/macrophage maturation promoting activity. In contrast, intact a-actinin,
which is a 100-kDa actin-binding protein, has no differentiating activity. The aim of this study was to investigate the enzyme responsible for
the degradation of a-actinin to form this fragment, named mactinin. The ability of cell lysates to degrade [125I]a-actinin in the presence of
various enzyme inhibitors, including inhibitors of metalloproteinases, cysteine proteinases, and serine proteases, was measured.
Phenylmethylsulfonyl fluoride (PMSF) was the only inhibitor able to prevent formation of mactinin by cell lysate degradation of a-
actinin, suggesting that a serine protease is responsible for the digestion. Of the various serine proteases tested (thrombin, plasmin, and
urokinase), only urokinase was able to produce a 31-kDa band. The urokinase-generated 31-kDa band promoted maturation in HL-60 cells.
Amiloride, a specific inhibitor of urokinase, inhibited production of the 31-kDa a-actinin fragment by HL-60 cell lysates. For in vivo tests,
inflammatory fluid (from bronchoalvelolar lavage) was collected from uPA (urokinase) knockout mice and their wild-type counterparts after
intratracheal challenge with Pneumocystis carinii. Although most (6 of 8) wild-type mice had mactinin in their inflammatory fluid samples,
none (0 of 8) of the uPA knockout mice had mactinin present (P< 0.01). These results demonstrate that urokinase is necessary and sufficient
for the formation of the monocyte/macrophage maturation promoting fragment, mactinin, in vitro and in vivo. These findings support the role
of urokinase in the regulation of monocyte/macrophage functions, such as that occurring in inflammatory reactions.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hematopoietic cell maturation is known to be a highly
regulated process in which a small population of primitive
cells mature in the bone marrow microenvironment. The
microenvironment is a complex reservoir of bioactive sub-
stances including growth factors, growth factor inhibitors
[1,2], adhesion molecules [3], and matrix-degrading
enzymes [4]. Regulation of the proteolytic activity in the
pericellular environment appears to be a primary mechanism
by which leukocyte function and the course of inflammation
are regulated [5].
We have shown that a 31-kDa fragment from the amino-
terminal end of a-actinin, which was initially isolated from
bone marrow stromal cultures, can promote monocyte/
macrophage maturation of HL-60 myeloid leukemia cells,
U-937 histiocytic lymphoma cells, and peripheral blood
monocytes [6]. Alpha-actinin is a cytoskeletal protein
present in a variety of cells and tissues [7–9] and one of
many actin binding proteins found in focal adhesion sites,
where cells attach to extracellular matrix (ECM) [10]. Focal
adhesion sites contain several proteins that are synthesized
and laid down during contact between cells and their
substratum [11]. We also have shown that a-actinin is
abundant in the bone marrow stroma matrix, presumably
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at focal adhesion sites, and reduced in the presence of HL-
60 myeloid leukemia cells [12]. Furthermore, lysates of HL-
60 cells or of peripheral blood monocytes degrade the
inactive 100-kDa a-actinin to produce the 31-kDa fragment,
which we have named mactinin, which can induce a mature
macrophage phenotype [12]. That is, we have demonstrated
that mactinin significantly increases lysozyme secretion and
tartrate-resistant acid phosphatase staining in peripheral
blood monocytes.
In the present study, we investigated the enzyme
responsible for mactinin formation by using various
common protease inhibitors. These included inhibitors of
(a) metalloproteinases, a family of enzymes that degrade
most ECM components [13], (b) cysteine proteinases
including lysosomal cathepsins [14], and (c) serine pro-
teases, including thrombin, plasmin, and urokinase-type
plasminogen activator, which degrade fibrin and ECM
proteins [15]. The results of enzyme inhibition studies,
the ability of exogeneous urokinase to form the active
fragment, and its presence in HL-60 cell lysates suggest
that urokinase is responsible for the formation of mactinin
in vitro.
To determine whether urokinase modulates mactinin
formation during inflammatory responses in vivo, we
examined bronchoalveolar lavage fluid (BAL) from mice
after intratracheal challenge with the opportunistic patho-
gen Pneumocystis carinii. Previous studies showed that
uPA (urokinase) knockout mice [16] demonstrate reduced
inflammatory cell recruitment and are susceptible to P.
carinii, in contrast to wild-type mice which mount inflam-
matory responses to P. carinii and clear the infection [17].
Consistent with our in vitro data, mactinin was present in
the BAL fluid of wild-type mice during clearance of
infection, but was absent in the uPA knockout mice
despite progressive P. carinii infection. These results
indicate that urokinase also mediates mactinin formation
in vivo.
2. Materials and methods
2.1. Chemicals
Alpha-actinin, EDTA, phenylmethylsulfonyl fluoride
(PMSF), N-ethylmaleimide (NEM), 1,10 phenanthroline,
trans-epoxysuccinyl-L-leucylamido (4-guanidino) butane
(E-64), Na-p-tosyl-L-lysine chloromethyl ketone (TLCK),
N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK),
peptostatin, thrombin, plasmin, amiloride, and aprotinin
were purchased from Sigma (St. Louis, MO). Urokinase
was purchased from Calbiochem (San Diego, CA).
2.2. Alpha-actinin radiolabeling
One milligram of chicken gizzard a-actinin in phosphate
buffer (0.1 M KH2PO4, pH 8) was incubated with 250 ACi
[125I]Bolton–Hunter reagent (NEN-Dupont, Boston, MA;
specific activity 4400 Ci/mmol) according to the manufac-
turer’s instructions. Radiolabeled a-actinin was then iso-
lated on a PD-10 column and found to have a specific
activity of approximately 1.6 105 cpm/Ag.
2.3. Cell culture
An adherent bone marrow stroma cell line previously
established in this laboratory [18] from a normal volunteer
donor was grown to confluence in tissue culture flasks
(Nunc, Naperville, IL) containing RPMI-1640 supple-
mented with 15% heat-inactivated fetal calf serum, and
50 Ag/ml gentamicin (GIBCO, Green Island, NY). After 6
days in stationary culture, the adherent layer was washed
with PBS, exposed to 1% Triton X-100 (vol/vol) for 30
min at room temperature, and subsequently washed with
PBS to remove most remaining cell nuclei and cytoskeletal
elements from ECM-coated flasks [19]. HL-60 cells
(1105/ml) were seeded on matrix-coated flasks and
grown for 3 days in RPMI media with 15% FCS and 50
Ag/ml gentamicin. We have previously reported that HL-60
cells grown on this matrix demonstrate a more mature
morphology, increased nonspecific esterase, activity, and
increased ability to form Fc rosettes [18]. Conditioned
media (CM) was harvested by removing the media,
centrifuging at 200 g for 4 min, and collecting the
supernatant.
2.4. Cell lysate preparation
Although lysates of control HL-60 cells, of mature HL-
60 cells grown on matrix, and of blood monocytes can each
degrade a-actinin to form the 31-kDa fragment [12], we
elected to use HL-60 cells grown on matrix for the inhib-
ition experiments. HL-60 cells grown on matrix (1.5–
2 106) were detached by exposure to 2 mM EDTA for 3
min at 37 jC followed by gentle pipetting. Suspension and
detached cells were combined, washed with PBS, then lysed
at 4 jC with 100-ml lysis buffer (1% Triton X-100, 50 mM
TrisCl, 5 mM CaCl2, pH 7.8) and stored at  20 jC until
the time of analysis.
2.5. Measurement of radiolabeled a-actinin degradation in
the presence of enzyme inhibitors
[125I]a-actinin (5 105 cpm) was incubated with an
aliquot of HL-60 cell lysate (1.5–2 106 cells) in the
absence or presence of various enzyme inhibitors for 2 h
at 37 jC. Enzyme inhibitors included 25 mM EDTA, 1 mM
1, 10 phenanthroline, 10 AM E-64, 2 mM NEM, 0.1 mM
PMSF, 50 Ag/ml TLCK, 100 Ag/ml TPCK, and 1 Ag/ml
peptostatin. Samples were then loaded on a 12% SDS-
polyacrylamide gel and electrophoresed. Gels were dried
on a gel dryer (Model 583, Bio-Rad, Hercules, CA) and
exposed to X-ray film (Kodak, Rochester, NY) with an
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intensifying screen at  70 jC. Densitometry measurements
of the 31-kDa fragment and 100-kDa a-actinin were per-
formed using a Power Look scanner (UMAX, Hsinchu,
Taiwan) and NIH Image Software.
2.6. Enzyme digestion of [125I] a-actinin by selected serine
proteases
[125I]a-actinin (5 105 cpm) was incubated with various
serine proteases at 37 jC. Thrombin and plasmin were used
at an enzyme/substrate ratio 1:10 for 2 h in 0.1 M TrisCl
digestion buffer, pH 8.0. Urokinase was used at 4000
Plough units at 37 jC in 0.1 M TrisCl digestion buffer pH
8.0, for 18 h. Samples were then electrophoresed on a 12%
SDS-polyacrylamide gel. The gel was then dried and auto-
radiography was performed as previously described.
2.7. Electroelution
From a companion lane of the SDS-polyacrylamide gel
containing the products of urokinase digestion of 10-Ag
unlabeled a-actinin, a 31-kDa band corresponding to that
detected by autoradiography or by silver staining was
excised and placed in dialysis tubing (Spectrum, Houston,
TX). Electroelution was carried out at 35 mA for 16 h in 192
mM glycine and 25 mM TrisCl. Samples were then dialyzed
against H2O and concentrated by a vacuum evaporator
(Savant, Farmingdale, NY) to a volume suitable for in vitro
maturation assays (less than 100 Al).
2.8. Assessment of maturation
As previously described for maturation assays [6], HL-60
cells were seeded at a density of 1105/ml and grown for 3
days in the presence of the urokinase-generated 31-kDa
degradation product of a-actinin that had been separated by
SDS-PAGE and electroelution. Maturation of HL-60 cells
was determined, as measured by nonspecific esterase activ-
ity [20] and Fc rosette formation [21,22].
2.9. Measurement of urokinase activity
Urokinase activity was measured using the chromogenic
substrate S-2444 (Chromogenix, Mo¨lndal, Sweden). Cell
lysates from 2 106 HL-60 cells grown on plastic or matrix
or CM from HL-60 cells grown on plastic or matrix and
concentrated using an Mr 10,000 Centricon membrane were
each incubated with aprotinin (10 KIU/ml) for 1 h to block
nonspecific protease activity. Samples were then incubated
with 3 mM S-2444 substrate, 50 mM TrisCl, 38 mM NaCl,
pH 8.8 for 5 min. The reaction was stopped with 2% acetic
acid. The optical absorbance was read at 405 nm with a
spectrophotometer (Beckman, Fullerton, CA) and urokinase
activity was estimated from a standard curve generated with
commercially prepared urokinase (Calbiochem, La Jolla,
CA).
2.10. Inhibition of a-actinin degradation by cell lysate with
amiloride
Amiloride specifically inhibits urokinase activity [23].
Lysate from 1106 HL-60 cells was incubated with ami-
loride (final concentration 2.5 mM) for 30 min at 37 jC then
incubated with [125I]a-actinin for 2 h at 37 jC and loaded
on an SDS-polyacrylamide gel.
2.11. Inflammatory BAL fluid from uPA knockout and wild-
type mice
Transgenic uPA-deficient mice (uPA / ) and back-
ground matched control mice (wild-type) were generous
gifts from Dr. Peter Carmeliet. These mice were developed
as previously described [16]. Genotype of the uPA knockout
mice was confirmed by PCR analysis as described previ-
ously [24]. Groups of uPA knockout mice and wild-type
mice were intratracheally inoculated with 1105 P. carinii
organisms, obtained from the lungs of chronically infected
C57BL/6 scid mice as previously described [17]. Two
weeks after inoculation, mice were exsanguinated during
deep pentobarbital anesthesia. A polyethylene catheter was
inserted into the trachea and the lungs were lavaged with 11-
ml PBS in 0.5-ml aliquots. Fluids from individual mice were
centrifuged at 500 g to remove cells and the supernatants
were frozen at  80 jC until analyzed. These animal studies
were approved by the Animal Care Committee, Ann Arbor
Veterans Affairs Medical Center.
2.12. Source of mactinin for antibody production
A pGEX2 vector, encoding the actin-binding domain,
residues 2–269 of chicken smooth muscle a-actinin, fused
with the C terminus of glutathione S-tranferase (GST) with
an engineered thrombin cleavage site, was kindly provided
by Dr. D.R. Critchley of the University of Leicester, UK.
Fusion protein was expressed in E. coli and purified by
affinity chromatography of cell extracts on immobilized
glutathione. The fusion protein was then cleaved with
thrombin to yield the actin-binding domain of a-actinin
and the GST carrier. The cleavage products were dialyzed
against 50 mM TrisCl, pH 7.5, then renatured in 5 mM
glutathione, and separated on a reverse phase HPLC C-4
column. The column was equilibrated with 0.1% trifluoro-
acetic acid and eluted with a 30–70% acetonitrile gradient
run at 1%/ml/min. Fractions eluting at 50–60% acetonitrile
contained the fragment as demonstrated by silver-stained
SDS-PAGE of the fractions and confirmed by Western blot
analysis using polyclonal antisera raised against 100-kDa
chicken a-actinin. The a-actinin fragment was >90% of the
total protein of pooled fractions with the remaining 10%
being carrier GST. The calculated molecular weight of this
a-actinin fragment was 30,700 Da, and this recombinant
fragment had monocyte/macrophage maturation-promoting
activity as measured by nonspecific esterase staining of
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treated HL-60 myeloid leukemia cells. Mactinin and GST
were routinely assayed for protein endotoxin using a Pyro-
tell chromogenic assay kit (Associates of Cape Cod, Woods
Hole, MA). If detected, endotoxin was removed using
endotoxin removal affinity resin.
2.13. Antisera generation
Antisera with sensitivity for detecting mactinin were
generated in rabbits with approval of the IACUC of the
Minneapolis Veterans Affairs Medical Center. Briefly, puri-
fied recombinant chicken a-actinin peptide was modified by
dinitrophenol coupling and injected into two New Zealand
white rabbits along with complete Freund’s adjuvant. Boosts
were done with peptide and incomplete Freund’s adjuvant.
Antisera were screened for ability to detect the immunizing
peptide and immunoaffinity-purified using columns of the
recombinant fragment covalently bound to an Affi-Gel 15
Matrix (Bio-Rad). We anticipated cross-reactivity of the
purified antisera with fragments from rats, mice, or humans
due to the highly conserved amino acid sequence.
3. Results
3.1. The serine protease inhibitor PMSF inhibits the
generation of the 31-kDa a-actinin fragment by cell lysate
Monocytes and macrophages produce many secretory
products [25] and contain various proteases, which may
play important roles in modulating ECM [26]. We hypothe-
sized that mature HL-60 cells, like monocytes, produce an
enzyme which is responsible for a-actinin degradation. To
test this hypothesis we examined the effect of various
enzyme inhibitors on degradation of radiolabeled a-actinin
by mature HL-60 cell lysates using SDS-PAGE. Although
different lysates and different samples of radiolabeled a-
actinin varied in the extent of uninhibited degradation, the
effect of the inhibitors was reproducible.
Fig. 1. Inhibition of a-actinin degradation. Lysates of HL-60 cells grown on
bone marrow matrix were incubated with various metalloproteinase and
cysteine proteinase inhibitors prior to incubation with [125I]a-actinin. The
degradation products were then subjected to SDS-PAGE followed by
autoradiography. The ratio of densitometry readings for 31-kDa and 100-
kDa material is given for each lane, expressed as a percentage.
Fig. 2. Inhibition of a-actinin degradation by serine protease inhibitors. HL-
60 lysate, inhibitors, and [125I]a-actinin were incubated and subjected to
SDS-PAGE followed by autoradiography. Formation of the 31-kDa band
was assessed by densitometry.
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Metalloproteinases are an important group of enzymes
produced by mononuclear cells [27] to degrade ECM [28],
and their secretion is altered during cell differentiation.
EDTA and 1,10 phenanthroline are both inhibitors of metal-
loproteinases, but neither showed inhibition of cell lysate
degradation of a-actinin (Fig. 1). We further tested the
cysteine proteinase inhibitors, NEM and E-64. Again, as
shown in Fig. 1, formation of the 31-kDa fragment was not
inhibited. We then tested various serine protease inhibitors,
including PMSF, TLCK, TPCK, and peptostatin. As shown
in Fig. 2, PMSF was the only inhibitor to inhibit the
formation of a 31-kDa degradation product. This suggests
that the active enzyme in the cell lysate is a serine protease.
3.2. Urokinase digests a-actinin to produce a 31-kDa band
Serine proteases are a large group of enzymes which are
present in vivo and include coagulation factors, plasmino-
gen activators, plasmin, thrombin, subtilisin, trypsin, prop-
ardin, pronase, kallikrein, endopeptidases, chymotrypsin,
and complement factor-1. We elected to test some of the
more physiologically relevant of these enzymes for a-
actinin degradation. Fig. 3 shows the results of incubating
[125I]a-actinin with various serine proteases. Although
thrombin and plasmin were able to degrade a-actinin, only
urokinase was able to produce a 31-kDa a-actinin fragment.
3.3. Urokinase-generated 31-kDa a-actinin fragment in-
duces HL-60 cell maturation
Degradation products of a-actinin digestion by urokinase
were separated by SDS-PAGE, and the 31-kDa band was
electroeluted and tested for maturation-promoting activity
using the HL-60 cell line. Fig. 4 shows the induction of two
markers of monocyte/macrophage maturation, Fc rosette
formation and esterase staining. The electroeluted 31-kDa
band had maturation promoting activity similar to that of
12-0-tetradecanoylphorbol-13-acetate (TPA), a strong
inducer (positive control).
3.4. Mature HL-60 cells release urokinase activity
HL-60 cells grown on bone marrow matrix express a
mature macrophage-like phenotype [18]. Lysates of these
cells and CM from these cultures were tested for urokinase
activity. As shown in Table 1, lysate of mature HL-60 cells
grown on matrix contained urokinase activity, as did CM
from cultures on matrix. In contrast, lysates of HL-60 cells
grown on plastic or CM from these cultures contained no
detectable urokinase activity ( < 2 IU), suggesting that
urokinase activity increases with maturation.
Fig. 3. Degradation of a-actinin by serine proteases. [125I]a-actinin was
incubated with the serine proteases thrombin, plasmin, or urokinase and
subjected to SDS-PAGE followed by autoradiography. Formation of the 31-
kDa band was again assessed by densitometry.
Fig. 4. The urokinase-generated 31-kDa fragment of a-actinin induces HL-
60 cell maturation, as measured by Fc rosette formation or nonspecific
esterase staining. Data are meansF S.D. This represents one of two
experiments with similar results. Fifty-four percent of cells treated with the
positive control, TPA, formed Fc rosettes and 84% demonstrated
nonspecific esterase staining. Only 24% of untreated cells formed rosettes
and 14% showed nonspecific esterase staining.
Table 1
Mature HL-60 cells grown on matrix contain and release more urokinase
than control HL-60 cells
IU Urokinase/106 cells
HL-60/plastic cell lysate < 2
HL-60/matrix cell lysate 11F 0
CM of HL-60/plastic < 2
CM of HL-60/matrix 9.8F 2.7
After 72 h of culture, HL-60 cells grown on plastic or bone marrow matrix
were harvested. Concentrated CM and cell lysate from 2 106 cells were
incubated with 10 KIU/ml aprotonin for 1 h to block nonspecific protease
activity, then assayed for urokinase activity using the S-2444 substrate and
the acid stop method per manufacturer’s instructions.
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3.5. The urokinase inhibitor, amiloride, inhibits the
generation of the active 31-kDa a-actinin fragment
To further confirm that urokinase is the enzyme in HL-60
cell lysates responsible for the formation of the active a-
actinin fragment, cell lysates from 2 106 mature HL-60
cells were incubated with a-actinin in the presence or
absence of amiloride. Amiloride, a diuretic drug, inhibits
urokinase activity, but does not affect tissue-type plasmi-
nogen activator, plasmin, plasma kallikrein, or thrombin
[23]. As shown in Fig. 5, amiloride effectively inhibited the
formation of the 31-kDa band.
3.6. Mactinin is absent in inflammatory fluid from uPA
knockout mice
Affinity-purified rabbit antiserum raised against a
recombinant chicken a-actinin fragment detects picogram
amounts of the immunizing peptide. As shown in Fig. 6, this
antiserum reacts with a protein of the expected molecular
weight in mouse BAL fluid. BAL fluid from 6 of 8 wild-
type mice challenged intratracheally with P. carinii demon-
strated mactinin bands. In contrast, BAL fluid from 0 of 8
infected uPA knockout mice challenged intratracheally with
P. carinii demonstrated detectable fragment, despite pro-
gressive infection (P < 0.01 by Fisher’s exact test). To
ensure that mactinin formation depended upon the inflam-
matory response, BAL fluid from 4 wild-type and 4 uPA
knockout mice that were not challenged with P. carinii was
tested for mactinin. None was detected [data not shown].
4. Discussion
4.1. Regulation of cell maturation by the microenvironment
Hematopoeitic cell maturation is a complex process in
which cells mature in close contact with the ECM. This
process is regulated by signals from various cell adhesion
molecules and is influenced by various cytokines and
peptides [1–3]. Not only is the ECM considered a source
of regulatory signals for maturation, but in turn, cells
Fig. 5. The urokinase inhibitor amiloride inhibits the generation of the
active 31-kDa band by cell lysate. Lysate of HL-60 cells grown on bone
marrow matrix was incubated with amiloride prior to incubation with
[125I]a-actinin. The degradation products were then subjected to SDS-
PAGE followed by autoradiography.
Fig. 6. Western blot analysis using affinity-purified antisera raised against the recombinant chicken a-actinin fragment. In the mouse, the calculated molecular
weight of the fragment is 820 Da more than in the chicken or 31.8 kDa. Lanes A–H each contain 0.7-ml BAL fluid from wild-type mice challenged
intratracheally with P. carinii during clearance of infection. Lanes I–P contain 0.7-ml BAL fluid from uPA knockout mice challenged intratracheally with P.
carinii during progressive infection. The last row contains recombinant chicken fragment in the amount shown. Two bands appear due to an alternate thrombin
cleavage site in the fusion protein.
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modify the ECM by secreting various products which
function to degrade and remodel it [4]. This interaction
between cells and their microenvironment is felt to be
important in immunity, inflammation, and homeostasis
[29–31].
We previously reported that CM from HL-60 cells grown
on bone marrow ECM induces monocyte/macrophage-like
maturation of other HL-60 cells [18,32]. We isolated a 31-
kDa fragment of a-actinin, now named mactinin, from this
CM which was able to promote macrophage maturation of
various cells, including U-937 histiocytic lymphoma cells,
and peripheral blood monocytes [6]. We also have shown
that a-actinin is abundant in the bone marrow ECM at focal
adhesion sites where cells are in close contact with their
substratum [12]. The present work focused on the potential
mechanism through which mactinin, the maturation-promot-
ing a-actinin fragment, is formed.
4.2. Urokinase degrades a-actinin to form mactinin in vitro
Alpha-actinin is a 100-kDa actin-binding protein found at
focal contact sites [10]. Cell lysates of HL-60 cells or
peripheral blood monocytes are able to degrade inactive
100-kDa a-actinin into the active 31-kDa fragment [12],
suggesting that the lysates contain an enzyme(s) which
degrades a-actinin. Using various enzyme inhibitors, we
now show that a serine protease is likely to be responsible
for this degradation. Of the various serine proteases tested,
urokinase was able to degrade a-actinin to produce a 31-
kDa fragment with differentiating activity. Furthermore, the
urokinase specific inhibitor, amiloride, inhibited the forma-
tion of this fragment by HL-60 cell lysates. Indeed, uroki-
nase activity was secreted by mature HL-60 cells.
4.3. Urokinase activity in inflammation
The expression of urokinase activity is intimately
involved in the course of inflammatory responses [33].
For example, in the mouse excisional wound model, uroki-
nase activity increases during the healing process, then
returns to undetectable baseline levels by the time of wound
closure [34]. The expression of urokinase is also up-regu-
lated in macrophages cultured on ECM [35], and levels of
urokinase and other proteases serve as useful markers of
macrophage activation [36]. This supports our finding that
mature HL-60 cells grown on ECM contain more urokinase
activity than control HL-60 cells.
Urokinase is thought to play a central role in regulating
extracellular proteolysis in a variety of normal and patho-
logical processes involving tissue destruction and cell migra-
tion [37,38]. Of note, endothelioma cells [39] and
macrophages [16] from urokinase knockout mice display
reduced ability to degrade extracellular matix. Many cells
that secrete urokinase also express specific high-affinity
plasma membrane binding receptors (u-PAR) [40,41] which
bind urokinase to allow localized proteolytic activity. These
receptors may also protect urokinase from enzyme inhibition
[42]. The urokinase-like plasminogen activator and its
receptor is the most thoroughly known and studied cell
surface proteolytic system [43]. This system has been shown
to be directly involved in several steps of tumor cell invasion
[44,45] and in inflammatory responses [46]. It appears, from
studies of animals with targeted inactivation of various
fibrinolytic genes, that urokinase alone, without the uroki-
nase receptor or tissue-type plasminogen activator, is suffi-
cient to support the tissue remodeling of wound repair [47].
4.4. Urokinase degradation of extracellular proteins
When peripheral blood monocytes adhere to the stroma
or endothelial cells, they cause retraction or movement [48]
at the leading edge, uncovering focal adhesion sites which
become directly accessible for degradation by enzymes such
as urokinase [49]. This retraction or movement is also
accompanied by increased membrane permeability, which
may allow the release of high molecular weight intracellular
proteins [48]. Both urokinase and urokinase receptors are
localized at focal adhesion sites [50]. Previous investigators
have shown that urokinase receptors bind to vitronectin and
integrin at distinct sites from urokinase binding to form a
stable complex [51–55]. Thus, integrin may facilitate inter-
action between urokinase and cytoskeletal proteins such as
a-actinin at focal adhesion sites. These enzyme/receptor/
substrate complexes may allow proteolysis to occur at a
high enzyme/substrate ratio [56].
The proteolytic degradation of various ECM proteins by
other members of the plasminogen activator system is well
established [57,58]. For example fibronectin is digested by
thrombin to yield two large and one small fragments [59]. A
fragment of fibronectin was shown to induce the expression
of stromalysin mRNA and cause chondrocyte chondrolysis
[60]. Also, plasmin activated by urokinase binds and
degrades several components of the ECM, including fibro-
nectin, laminin, and proteoglycan [61,62].
4.5. Urokinase is required for mactinin formation in vivo
Mactinin’s absence in inflammatory fluid from uPA
(urokinase) knockout mice is consistent with the results of
our in vitro studies that show that urokinase is necessary for
mactinin formation. Our findings may have broad physio-
logical relevance in any inflammatory process in which
urokinase and macrophages play essential roles [63]. The
urokinase knockout mice have deficient macrophage recruit-
ment in response to infection [17] and other inflammatory
conditions [64]. We have recently demonstrated that macti-
nin, in addition to promoting monocyte/macrophage matu-
ration, is chemotactic for monocytes [unpublished data].
Although mactinin may be a unique regulator of monocyte/
macrophage response to infection and inflammation, it may
not be absolutely necessary for normal response, as it was
not detectable in two of the wild-type mice. We are currently
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investigating how mactinin interacts with monocytes to
signal maturation.
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